Argent BioPharma (RGT) Share Price, News & Analysis

Company Overview

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Key Stats

• Today's Range: 16.66 to 16.75
• 50-Day Range: N/A
• 52-Week Range: 10 to 24
• Volume: 1 shs
• Average Volume: 6,162 shs
• Market Capitalization: £8.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RGT Stock Analysis - Frequently Asked Questions

How have RGT shares performed this year?

Argent BioPharma's stock was trading at GBX 16.15 at the beginning of the year. Since then, RGT stock has increased by 3.2% and is now trading at GBX 16.66.
View the best growth stocks for 2024 here.

How do I buy shares of Argent BioPharma?

Shares of RGT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:RGT
• CUSIP: N/A
• CIK: N/A
• Web: argentbiopharma.com
• Phone: 61-8-6555-2950
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-17,530,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -108.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX (11) per share
• Price / Book: -1.52

Miscellaneous

• Outstanding Shares: 48,410,000
• Free Float: N/A
• Market Cap: £8.11 million
• Optionable: N/A
• Beta: 1.05